SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : Oravax(orvx) -- Ignore unavailable to you. Want to Upgrade?

To: LTK007 who wrote (99)12/9/1998 11:08:00 PM
From: Ploni  Respond to of 127
 
The additional milestone payments and research and development funding through market approval of a dengue vaccine is estimated at up to about $16.5 million.

Wow! That's a buck a share. I figured the stock was worth around $1/share when the takeover by Peptide was announced, and have been amazed that it's trading so low. This new deal should thrill Peptide, and should make the combined company even more valuable. It's too bad that I can't pick up more ORVX stock at these prices, but I'm not willing to give the market makers a free ride -- I only buy stocks that have thin spreads.

This press release: oravax.com , from Oravax's website, gives additional background.

And here's the press release from Peptide, giving their take:
194.202.157.11



To: LTK007 who wrote (99)12/10/1998 2:32:00 PM
From: BobbleUnc  Read Replies (1) | Respond to of 127
 
Thanks for your perspective Max. That much of a spread seemed unusual for a stock less than 50 cents. I agree with the long term approach to this one. The news is quite exciting, both bio-medically and financially for ORVX.
thanks again,
Bobb

I've just begun accumulating. Looking forward to the day we can reap some.....


HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2026 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News